Biotech

Biotech Andrew Joseph

STAT Plus: Roche to launch another Elevidys trial, with eyes on European approval

Adam's Biotech Scorecard Adam Feuerstein

STAT Plus: Travere’s drug for a kidney disease doesn’t improve kidney function. The FDA approved it anyway

The Readout Elaine Chen

STAT Plus: Novartis CEO joins Anthropic’s board

Biotech Allison DeAngelis

STAT Plus: New Bain biotech startup, building on BMS drugs, gets a name and a CEO

The Readout Elaine Chen

STAT Plus: FDA pressures drugmakers to report trial results

First Opinion Nathan Grant

My brother can’t access a just-approved breakthrough drug for his rare disease

Biotech Angus Chen

For Ben Sasse, Revolution Medicines’ pancreatic cancer trial felt like his best, only option

The Readout Meghana Keshavan

STAT Plus: GSK advancing ovarian cancer drug mo-rez

Biotech Jason Mast

STAT Plus: Revolution Medicines touts ‘unprecedented’ data for pancreatic cancer pill

Biotech Adam Feuerstein

STAT Plus: Allogene Therapeutics’ CAR-T treatment eliminates residual cancer cells in B-cell lymphoma patients

Biotech Allison DeAngelis

STAT Plus: Spyre Therapeutics IBD drug shows promise in early trial

Biotech Jason Mast

STAT Plus: Replimune skin cancer drug that became FDA flashpoint is rejected again

The Readout Meghana Keshavan

STAT Plus: A new trick for old science, and biotech VCs’ scrambled playbook

Health Isabella Cueto

STAT Plus: 5 years after lupus breakthrough, CAR-T is still surprising autoimmunity researchers

The Readout Meghana Keshavan

STAT Plus: Genetics may shape GLP-1 outcomes, slightly

Biotech Allison DeAngelis

STAT Plus: Biotech VCs, used to a winning formula in drug development, face disruption

The Readout Elaine Chen

STAT Plus: Terns’ drug may not be as competitive as many initially thought

Special Report Jason Mast

STAT Plus: A decade ago, these drugs tore apart the FDA. Today, they might be some patients’ best hope

The Readout Elaine Chen

STAT Plus: Novo Nordisk launches high-dose Wegovy

Health Angus Chen

STAT Plus: Many cancer patients don’t get genomic tests to guide treatment, study finds

Biotech Andrew Joseph

STAT Plus: Gilead to buy cancer biotech Tubulis for more than $3 billion

Politics John Wilkerson and Lizzy Lawrence

STAT Plus: FDA backs proposals to entice pharma companies to test, make drugs domestically

The Readout Meghana Keshavan

STAT Plus: Stealth biotech Stipple bets on secretive ADCs

Biotech Allison DeAngelis

STAT Plus: Neurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal

Biotech Elaine Chen

STAT Plus: How a four-month FDA delay forced a small biotech company to close its doors

The Readout Meghana Keshavan

STAT Plus: Biotech investors’ plea to Trump, and a busy M&A week

Exclusive Daniel Payne

STAT Plus: Small drugmakers, facing threat of tariffs, negotiate pricing deals with White House

Biotech Daniel Payne

STAT Plus: Trump announces 100% tariffs on brand-name drugs, with plenty of carveouts

The Readout Meghana Keshavan

STAT Plus: Lilly’s obesity pill enters the oral GLP-1 game, Novo responds